Literature DB >> 15930144

Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction.

Lindsay M Angus1, Joe V Chakkalakal, Alexandre Méjat, Joe K Eibl, Guy Bélanger, Lynn A Megeney, Eva R Chin, Laurent Schaeffer, Robin N Michel, Bernard J Jasmin.   

Abstract

We examined whether calcineurin-NFAT (nuclear factors of activated T cells) signaling plays a role in specifically directing the expression of utrophin in the synaptic compartment of muscle fibers. Immunofluorescence experiments revealed the accumulation of components of the calcineurin-NFAT signaling cascade within the postsynaptic membrane domain of the neuromuscular junction. RT-PCR analysis using synaptic vs. extrasynaptic regions of muscle fibers confirmed these findings by showing an accumulation of calcineurin transcripts within the synaptic compartment. We also examined the effect of calcineurin on utrophin gene expression. Pharmacological inhibition of calcineurin in mice with either cyclosporin A or FK506 resulted in a marked decrease in utrophin A expression at synaptic sites, whereas constitutive activation of calcineurin had the opposite effect. Mutation of the previously identified NFAT binding site in the utrophin A promoter region, followed by direct gene transfer studies in mouse muscle, led to an inhibition in the synaptic expression of a lacZ reporter gene construct. Transfection assays performed with cultured myogenic cells indicated that calcineurin acted additively with GA binding protein (GABP) to transactivate utrophin A gene expression. Because both GABP- and calcineurin-mediated pathways are targeted by peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha), we examined whether this coactivator contributes to utrophin gene expression. In vitro and in vivo transfection experiments showed that PGC-1alpha alone induces transcription from the utrophin A promoter. Interestingly, this induction is largely potentiated by coexpression of PGC-1alpha with GABP. Together, these studies indicate that the synaptic expression of utrophin is also driven by calcineurin-NFAT signaling and occurs in conjunction with signaling events that involve GABP and PGC-1alpha.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15930144     DOI: 10.1152/ajpcell.00196.2005

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  27 in total

Review 1.  Role of exercise in maintaining the integrity of the neuromuscular junction.

Authors:  Hiroshi Nishimune; John A Stanford; Yasuo Mori
Journal:  Muscle Nerve       Date:  2013-12-17       Impact factor: 3.217

2.  Sarcolipin deletion in mdx mice impairs calcineurin signalling and worsens dystrophic pathology.

Authors:  Val A Fajardo; Paige J Chambers; Emma S Juracic; Bradley A Rietze; Daniel Gamu; Catherine Bellissimo; Frenk Kwon; Joe Quadrilatero; A Russell Tupling
Journal:  Hum Mol Genet       Date:  2018-12-01       Impact factor: 6.150

3.  PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy.

Authors:  Christoph Handschin; Yvonne M Kobayashi; Sherry Chin; Patrick Seale; Kevin P Campbell; Bruce M Spiegelman
Journal:  Genes Dev       Date:  2007-04-01       Impact factor: 11.361

4.  Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse muscles.

Authors:  Aymeric Ravel-Chapuis; Ali Al-Rewashdy; Guy Bélanger; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2018-10-01       Impact factor: 6.150

5.  Calcium-binding proteins in skeletal muscles of the mdx mice: potential role in the pathogenesis of Duchenne muscular dystrophy.

Authors:  Adriana Pertille; Candida Luiza Tonizza de Carvalho; Cintia Yuri Matsumura; Humberto Santo Neto; Maria Julia Marques
Journal:  Int J Exp Pathol       Date:  2009-12-03       Impact factor: 1.925

Review 6.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

7.  Combinatorial therapeutic activation with heparin and AICAR stimulates additive effects on utrophin A expression in dystrophic muscles.

Authors:  Christine Péladeau; Aatika Ahmed; Adel Amirouche; Tara E Crawford Parks; Lucas M Bronicki; Vladimir Ljubicic; Jean-Marc Renaud; Bernard J Jasmin
Journal:  Hum Mol Genet       Date:  2015-10-22       Impact factor: 6.150

Review 8.  The functional role of calcineurin in hypertrophy, regeneration, and disorders of skeletal muscle.

Authors:  Kunihiro Sakuma; Akihiko Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-04-01

9.  Targeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function.

Authors:  Yifan Lu; Chai Tian; Gawiyou Danialou; Rénald Gilbert; Basil J Petrof; George Karpati; Josephine Nalbantoglu
Journal:  J Biol Chem       Date:  2008-10-21       Impact factor: 5.157

10.  Heregulin-induced epigenetic regulation of the utrophin-A promoter.

Authors:  Utpal Basu; Mads Gyrd-Hansen; Santhosh M Baby; Olga Lozynska; Thomas O B Krag; Claus J Jensen; Morten Frödin; Tejvir S Khurana
Journal:  FEBS Lett       Date:  2007-07-23       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.